The solutions to America's drug cost dilemma (and why they won't happen)
Skip to main content
MDHC_Logotype_white
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • This Week's News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • People
    • Regional News
    • Digital Edition
    • Highlights of the $1.9T COVID bill nearing final passage
      By the Numbers: Insurers owing largest MLR rebates
      A younger woman provider helping an older woman on a tablet.
      Insurers set sights on growth in Medicare Advantage, Medicaid managed care
      Artist Gus Moran begins his chalk art piece Feb. 28 at the Disneyland Resort Vaccine Super Site POD.
      City of Hope commissions street art to spread positive messages
    • Highlights of the $1.9T COVID bill nearing final passage
      Artist Gus Moran begins his chalk art piece Feb. 28 at the Disneyland Resort Vaccine Super Site POD.
      City of Hope commissions street art to spread positive messages
      The COVID-19 experience and its influence on post-pandemic health policy
      A close-up of President Joe Biden wearing a mask.
      Healthcare industry gearing up to try to find common ground with Biden
    • Shareholder group calls out HCA for alleged excessive emergency department admissions
      Metrologo 600x400_i.jpg
      MetroHealth forms Center for Cancer Research
      The Check Up: Dr. Marc Boom
      The Check Up: Dr. Marc Boom of Houston Methodist
      Dr. Marc Boom
      Q&A: Houston Methodist CEO praises staff efforts to keep vaccine efforts going during ice storm
    • A younger woman provider helping an older woman on a tablet.
      Insurers set sights on growth in Medicare Advantage, Medicaid managed care
      By the Numbers: Insurers owing largest MLR rebates
      5 things to know about Alignment Healthcare's proposed IPO
      Solid sign-ups for Biden's new Obamacare coverage offer
    • MedPAC likely to recommend an effective cut in Medicare Advantage spending
      MedPAC likely to recommend CMS simplify alternative payment models
      Florida governor faces growing charges of vaccine favoritism
      States rapidly expanding vaccine access as supplies surge
    • 369178053.jpg
      Shares of insurer Oscar Health fall following $1.4B IPO
      Sutter Health posts sizable 2020 loss, announces sweeping review of finances
      UPMC's patient volumes stabilize, boosting 2020 profits
      Genomics firms taking advantage of SPACs trend to go public faster
    • Abbott gets emergency use authorization for test that detects COVID-19, other infections
      Insurance regulator to issue warning on virus-test billing
      351532635.jpg
      Red-hot virtual care market propels New York City health startups to record year
      Teladoc reports $383.3M in fourth-quarter revenue, up 145%
    • Artist Gus Moran begins his chalk art piece Feb. 28 at the Disneyland Resort Vaccine Super Site POD.
      City of Hope commissions street art to spread positive messages
      54.2% of teens were fully vaccinated against HPV in 2019, compared with 51.1% in 2018. 79 million: Estimated number of Americans currently infected with HPV.
      Data Points: Another vaccination race for HPV
      Doctors performing surgery
      Doctor appears in court video call while performing surgery
      Diagnostic developers hedge on coronavirus rapid antigen tests, citing conflicting FDA messages
    • Francoise_Adan1_i.jpg
      Cleveland's UH creates position of chief whole health and well-being officer
      Alicia Wilson
      Q&A: Emerging leader Alicia Wilson on staying close to home
      Michael Jordan, Novant team up to address health equity
      Former Ascension CEO, the first to lead the health system, passes away
    • Midwest
    • Northeast
    • South
    • West
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
    • The Affordable Care Act after 10 years
    • Dr. John Fischer
      Patient-reported outcomes tool for hernia surgery helps physicians improve care
      New care model helps primary-care practices treat obesity
      doctor with patient
      COVID-19 treatment protocol developed in the field helps patients recover
      Rachel Wyatt
      Project to curb pressure injuries in hospitals shows promise
    • What's next for on-demand telehealth companies?
      A CalOptima PACE vaccination clinic.
      Will COVID-19 be the catalyst for creating a more sustainable healthcare system?
      A map of the U.S. with images of the coronavirus.
      The digital divide becomes a new social determinant of health
      Ascension’s St. Mary’s Hospital Surgery Center at Towne Centre and Allegheny Health Network’s Bethel Park surgery center
      Hospitals see opportunity, risk in ambulatory surgery centers
    • Ryan McGinnis
      Finding efficiencies in the OR using tech
      Dr. Daniel Hall
      UPMC pilots machine learning, telehealth to inform patient transfers
      A woman being recorded using her inhaler on a smartphone.
      Digital check-ins, connected inhalers help control asthma
      A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
  • Transformation
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • What's next for on-demand telehealth companies?
      Rising prescription copays drop adherence, spike mortality, research shows
      Dr. John Fischer
      Patient-reported outcomes tool for hernia surgery helps physicians improve care
      Highmark Health inks six-year cloud, tech deal with Google
    • Ryan McGinnis
      Finding efficiencies in the OR using tech
      Hospitals' Medicare billing practices suggest upcoding, OIG says
      California hospitals prepare ethical protocol to prioritize lifesaving care
      Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven
    • Dr. Daniel Hall
      UPMC pilots machine learning, telehealth to inform patient transfers
      A woman being recorded using her inhaler on a smartphone.
      Digital check-ins, connected inhalers help control asthma
      Humana partners with in-home provider for 24/7 care
      A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
    • MedPAC likely to recommend CMS simplify alternative payment models
      Bundled payments reduce surgery costs by 10.7%
      Coordinated payment policies could speed transition to value, experts say
      CMMI's geographic direct contracting model needs an overhaul, experts say
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
    • Health Systems Financials
      Executive Compensation
      Physician Compensation
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
    • Dr. Alan Kaplan
      The risks, rewards of taking organizations 'where they haven’t gone before'
      Wellstar CEO calls adapting for the pandemic her bold move
      Howard P. Kern
      Recognizing the value of telehealth in its infancy
      Dr. Stephen Markovich
      A bold move helped take him from family doctor to OhioHealth CEO
    • Dr. Stephen Markovich
      Making sure we're aligned along the path to achieving inclusion
      Barry Ostrowsky
      Ending racism is a journey taken together; the starting point must be now
      Laura Lee Hall and Gary Puckrein
      Increased flu vaccination has never been more important for communities of color
      John Daniels Jr.
      Health equity: Making the journey from buzzword to reality
    • The COVID-19 experience and its influence on post-pandemic health policy
      Haven is history, but its mission is the future of healthcare
      Vaccinating children could be the key to ending the pandemic
      Mikelle Moore
      The promising future of rural healthcare, even amid the COVID-19 pandemic
    • Letters: Eliminating bias in healthcare needs to be ‘deliberate and organic’
      Letters: Maybe dropping out of ACOs is a good thing for patients
      Letters: White House and Congress share blame for lack of national COVID strategy
      Letters: VA making strides to improve state veterans home inspections
    • Sponsored Content Provided By Optum
      How blockchain could ease frustration with the payment process
      Sponsored Content Provided By Optum
      Three steps to better data-sharing for payer and provider CIOs
      Sponsored Content Provided By Optum
      Reduce total cost of care: 6 reasons why providers and payers should tackle the challenge together
      Sponsored Content Provided By Optum
      Why CIOs went from back-office operators to mission-critical innovators
  • Awards
    • Award Programs
    • Nominate
    • Previous Award Programs
    • Other Award Programs
    • Best Places to Work in Healthcare Logo for Navigation
      Nominations Open - Best Places to Work in Healthcare
      Nominations Open - 50 Most Influential Clinical Executives
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Minorities in Healthcare
      • - Luminaries
      • - Top 25 Minority Leaders
      • - Minorities to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Excellence in Nursing Awards
    • Design Awards
    • Top 25 COOs in Healthcare
    • 100 Top Hospitals
    • ACHE Awards
  • Events
    • Conferences
    • Galas
    • Webinars
    • COVID-19 Event Tracker
    • podium march webinar logo lockup
      Sponsored Content Provided By Podium
      Webinar: Critical Touchpoints for Every Patient’s Journey — How Technology Plays an Important Role
      scp health logo lockup march 2021
      Sponsored Content Provided By SCP Health
      Webinar: COVID’s call to action — Reset for success in 2021
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Healthcare Transformation Summit
    • Leadership Symposium
    • Virtual Briefings
      • - Hospital of the Future
      • - Mental Health
      • - Patient Safety & Quality
      • - Strategic Marketing
      • - Virtual Health
      • - Workplace of the Future
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Minority Leaders Gala
    • Top 25 Women Leaders Gala
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
    • Empty boardroom
      Next Up Podcast: What's going to happen tomorrow? Succession planning during emergencies
      Next Up Podcast: Educating patients on the COVID-19 vaccine with Tanya Andreadis
      Dr. Joseph Cacchione
      Next Up Podcast: Educating patients on the COVID-19 vaccine with Dr. Joseph Cacchione
      Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next four years
    • Beyond the Byline: Insurers are betting on virtual-first plans as COVID-19 shifts care pathways
      Beyond the Byline: How residents' stories shape our coverage of the vaccination rollout in nursing homes
      Beyond the Byline: Regulators aim to boost value push with fraud and abuse law updates
      An older man wearing a mask receiving a vaccine.
      Beyond the Byline: Verifying information on the chaotic COVID-19 vaccine rollout
    • Outreach during COVID-19
      Leading intention promote diversity and inclusion
      Introducing Healthcare Insider Podcast
    • The Check Up: Dr. Marc Boom
      The Check Up: Dr. Marc Boom of Houston Methodist
      The Check Up: Dr. Imran Andrabi
      The Check Up: Dr. Imran Andrabi of ThedaCare
      The Check Up: Tanya Blackmon
      The Check Up: Tanya Blackmon of Novant Health
      The Check Up: Dr. Patrick Hwu
      The Check Up: Dr. Patrick Hwu of the Moffitt Cancer Center
    • ivana naeymi-rad one on one intelligent medical objects
      Video: Ivana Naeymi Rad of Intelligent Medical Objects
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
October 01, 2016 01:00 AM

The solutions to America's drug cost dilemma (and why they won't happen)

Harris Meyer
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print
    Getty Images

    Patients are complaining their drugs are unaffordable. Insurers are protesting that specialty drug costs are forcing them to jack up premiums. State Medicaid directors say spiking pharmacy costs are forcing them to make painful coverage trade-offs.

    Congress has been grilling drug company executives over their big price hikes. Democratic presidential nominee Hillary Clinton has proposed unprecedented federal review of price hikes. Both Clinton and GOP nominee Donald Trump favor letting consumers buy cheaper drugs from foreign countries. Both also have said Medicare should negotiate prices with drugmakers, though Trump's campaign website doesn't mention this.

    But despite the growing political furor, the odds of significant federal action on drug costs this year or next are slim, experts say.

    That may surprise voters, given the torrents of rhetoric and promises from politicians. Yet the issue of how to make drugs more affordable for individual patients and society is so complex and sensitive—and drug industry opposition so formidable—that a comprehensive, politically viable approach to solving the problem has yet to emerge.

    The impasse has left patients, insurers and healthcare provider groups pushing for immediate relief from the most egregious price spikes, like Mylan's 550% list price increases over eight years on EpiPen epinephrine auto-injectors, a must-have product for counteracting allergic reactions.

    Some are hoping the EpiPen brouhaha will mark a tipping point in the debate. “This affects families and children, and it's a potentially life-threatening situation,” said John Rother, CEO of the National Coalition on Health Care and head of the Campaign for Sustainable Rx Pricing, a broad coalition of groups advocating market-based approaches to curbing drug costs. “It's a simpler problem to understand than the issues raised by other drugs.”

    Public opinion clearly backs quick action. A Kaiser Family Foundation survey last month found 77% of Americans say prescription drug costs are unreasonable, with 82% backing giving Medicare the power to negotiate drug prices.

    And the mounting public pressure has produced some results. One drugmaker, Allergan, recently promised to voluntarily limit price hikes on its products to once a year and keep them to single-digit percentage increases.

    But those are the exceptions—not the rule. Other drug companies are shifting the blame to insurers, arguing that health plans are pushing excessive costs on members through high deductibles and copayments.

    Making policy action tricky is that rising prices for generic, brand-name and biologic products each have different causes, and each requires a different set of policies to bring under control. And each category has its own set of stakeholders ready to thwart decisive action that would bring down prices.

    With brand-name drugs, many stakeholders have bought into the idea that lower prices will reduce the financial incentives for developing new breakthrough products. With biologics, patient and physician groups worry that potentially cheaper biosimilars may not have the same efficacy as the brand-name biologics they replace.

    There has been a greater willingness to target profiteering on generic and older branded products, where triple-digit price increases seem absurd on their face. But rising prices for generics have been triggered by a variety of factors, including a shortage of producers for harder-to-manufacture injectables. That leaves the remaining manufacturers with hard-to-counter market power.

    Ideology also gets in the way. Even after the election, it is unlikely Republicans and Democrats will reach an agreement on drug-cost legislation. That's particularly true for Democratic plans to give Medicare the power to negotiate prices for the Part D drug benefit program. There's at best an outside chance they could come together on narrow measures to enhance competition in the generic market.

    The powerful drug industry traditionally has been able to fend off government efforts to counter price hikes. It successfully lobbied Congress in 2003 to bar Medicare from negotiating prices in the new Part D program. The industry has been aided by opposition from physician and patient advocacy groups, who fear that cost-benefit calculations will be used to cut them off from high-priced but effective medicines.

    Indeed, fierce criticism from doctors and patients has the CMS taking a second look at its recent proposed rule to reduce Medicare Part B payments to doctors who administer expensive drugs in their offices, the most common mode for cancer chemotherapy drugs. Shifting to a lower mark-up and a higher facility fee was seen as a way to nudge them to use cheaper, equally effective alternatives.

    “Prospects for legislative change are not high and are probably a little ways off,” said Dr. Aaron Kesselheim of Harvard Medical School, who co-authored a recent JAMA article surveying various reform proposals. “But maybe things are starting to change in a way that might provide an opening for some reform.”

    “It's hitting the point where the drug cost issue has got everyone's attention, but I'm not sure what the coalition would be that would support heavy-handed government intervention,” said Chip Kahn, CEO of the Federation of American Hospitals, which is participating in the Campaign for Sustainable Rx Pricing.

    Outside the legislative arena, there is growing support for the idea that drug prices should be based on the value they provide for patients. A few private insurers and drug companies are experimenting with outcomes-based arrangements.

    MH Takeaway

    Despite growing outrage over the past two years' price spikes on specialty drugs, biologics and generics, a political solution seems as far away as ever. And drug industry lobbyists are planning a major post-election campaign to keep it that way.

    But these private-market initiatives are moving slowly because stakeholders are far from reaching a consensus on how value should be calculated. That was demonstrated by recent drug industry attacks on efforts by the not-for-profit Institute for Clinical and Economic Review to assess whether particular drugs are worth the price.

    “No one knows the answer to the question of value,” said Dr. Joshua Ofman, a senior vice president at Amgen, during an American Enterprise Institute panel discussion on drug pricing last month.

    That panel featured a contentious exchange between Ofman and two prominent advocates of value-based pricing, ICER CEO Dr. Steven Pearson and Dr. Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, New York. “We showed you our numbers; you show us your numbers,” Pearson said. “Let's all wrestle with that in public.”

    At stake in the battle is a U.S. drug market worth more than $350 billion a year. Prescription drug costs now account for about 17% of total U.S. healthcare spending and were the fastest rising component of that spending over the past year.

    List prices for prescription drugs rose more than 12% in 2015, although net prices rose only 2.8%, according to IMS Health. This year, most large drug companies reported that price increases boosted their revenue. Per capita spending in the Medicare Part D program rose 11.6% last year, more than in the past due partly to price spikes for brand-name drugs, according to the Medicare trustees' report.

    Despite all the talk about the need for action, when someone proposes or implements even relatively modest measures to address drug costs, there's often a furious backlash. One multiple myeloma patient wrote in an op-ed responding to ICER's critical evaluation of the prices of drugs to treat his cancer condition: “I'm horrified by ICER's cost-cutting proposals, which … would cost the lives of 44,000 myeloma patients over the next five years. I don't intend to be in that number.”

    Proposed policies for lowering drug prices

    Federal

    Patents: Limit patentability of trivial changes in innovative medicines

    Antitrust: Prohibit anticompetitive deals that delay generics

    Prices: Empower Medicare to negotiate Part D drug prices; require drugmakers to provide Medicaid level rebates for dual-eligible beneficiaries in Part D

    Formularies: Exclude high-priced drugs that have cheaper, comparable alternatives

    Value: Base prices on clinical outcomes

    Generics: Boost FDA funding to speed generic-drug reviews; encourage the FDA to OK products approved in other advanced countries; ease generic companies' access to brandname drug samples to increase alternative therapies

    Biologics: Review standards for determining bioequivalency

    States

    Substitution: Pass mandatory generic substitution laws with limited carve-outs; eliminate patient consent requirements

    Medicaid: Allow state programs to test value-based pricing and restrictive formularies

    Discounts: Empower state programs to pay no more than the rates negotiated for drugs by the Veterans Affairs Department

    Price hike reviews: Require drugmakers to report and justify significant planned increases

    Source: Modern Healthcare reporting; JAMA

    Emotional criticisms like this suggest that the American public may be unprepared for explicit efforts to evaluate whether a drug or other type of treatment is worth the cost—unlike in other advanced countries such as Great Britain that openly weigh costs versus benefits in making coverage decisions. “This is a no-go zone,” lamented Yevgeniy Feyman, a health policy researcher at the conservative-leaning Manhattan Institute. “Everyone immediately jumps to rationing and death panels.”

    Despite the sensitivity of the issue, Democratic standard-bearer Clinton has offered an ambitious package of measures to reduce drug costs. A bipartisan group of senators has offered legislation to make it easier to bring generic products to the market. A separate bipartisan Senate group introduced a bill to require drugmakers to tell HHS in advance why a price increase of more than 10% is justified.

    Major stakeholders also are weighing in. The Campaign for Sustainable Rx Pricing, which includes providers, insurers, employers and consumer groups, has outlined measures to boost price transparency, competition and value-based pricing. But even such market-based approaches may need federal legislation to provide funding and establish a data infrastructure, Rother said.

    Drug industry trade groups, aware that their public image has been tarnished, are rolling out major public relations campaigns. They are also massively boosting their lobbying to shoot down unwanted legislation and regulation.

    The Biotechnology Innovation Organization recently unveiled an “Innovation Saves” ad campaign featuring patients who have been helped by its members' products. The Pharmaceutical Research and Manufacturers of America trade group, according to Politico, is planning to spend hundreds of millions of dollars on a post-election ad campaign.

    “We're under pressure and scrutiny like never before,” Jim Greenwood, BIO's CEO, told Bloomberg. “We want to make the point that these drugs, whether they're expensive or not, do save lives.” At the same time, he blasted insurers for hurting consumers with high deductibles and coinsurance, and ripped pharmacy benefit managers for profiteering.

    Given pharma's clout in Washington, some drug price warriors are turning to the states. California and Ohio voters will decide ballot initiatives in November that would require state government programs to pay no more for prescription drugs than the prices paid by the U.S. Veterans Affairs Department, which negotiates rates and currently gets a 24% discount off average manufacturer prices.

    Pharma groups are spending tens of millions of dollars to defeat those ballot measures, arguing they would hurt patient access to innovative drugs. Independent observers caution that forcing drugmakers to offer big discounts to state programs could lead them to raise prices for private-sector customers.

    Elsewhere, Vermont recently passed a law requiring drugmakers to justify price hikes, while Maryland, Pennsylvania and other states are considering various price transparency measures.

    Those favoring action to curb drug costs hope public outrage triggered by the recent EpiPen controversy continues to boil. Spurred by widespread anger over price hikes, Hillary Clinton last month proposed a federal review process to determine if “outlier” price increases for long-established prescription drugs are justified. When the increases were deemed not merited, the government could buy and provide alternative therapies to patients, allow temporary importation of lower-priced drugs from foreign countries and fine the drug companies involved.

    Pharma groups and congressional GOP leaders quickly signaled their strong opposition to Clinton's proposal. “The Clinton approach to healthcare drives you to a one-payer system, and drives you to rationing, drives you to a place where most consumers don't want to go,” Ian Read, CEO of Pfizer, told investors last month.

    Clinton and other Democrats also have proposed letting HHS negotiate Part D prices. Experts warn, however, that this would have little impact unless Congress also authorized the agency to exclude certain drugs from the Medicare drug formulary, as the VA does.

    As an alternative, Republican leaders are touting legislation that will speed Food and Drug Administration approval of new drugs and devices; it was passed by the House and is pending in the Senate. “The most important way to keep prices down is … to pass the 21st Century Cures bill, which will move new treatments and drugs through the regulatory … process more rapidly and reduce their cost,” Republican Sen. Lamar Alexander, chairman of the Senate HELP Committee, told Morning Consult.

    But most experts say that legislation would have little downward impact on drug costs, with some saying it could actually increase costs by expanding the number of me-too and marginally effective products on the market. “Candidly, most Republicans would acknowledge it doesn't do much on drug prices other than encouraging more competition,” the Manhattan Institute's Feyman said.

    There may be better prospects for bipartisan bills to boost competition in the generic market. Republican Sen. Chuck Grassley of Iowa and several Senate Democrats recently introduced a bill to make it easier for generic producers to gain access to brand-name products to conduct testing of generic versions prior to the branded product's patent expiration.

    “Everyone should be able to agree that drug companies shouldn't use regulatory processes as a way to delay competition and keep prescription drug prices high,” said Democratic Sen. Amy Klobuchar of Minnesota, who co-sponsored the bill with Grassley.

    Grassley and Klobuchar also co-sponsored a bill to make it illegal for brand-name and generic manufacturers to enter into purported payoff agreements to delay the introduction of generic products.

    While strengthening generic competition could be the low-hanging fruit in tackling drug costs, ICER's Pearson cautioned that in pharmacy policy and politics, nothing is ever simple. “Even the no-brainers end up being more complicated than we think they are,” he said.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Feds shouldn't lose sight of drug misuse epidemic, GAO says
    Feds shouldn't lose sight of drug misuse epidemic, GAO says
    States easing virus restrictions despite experts' warnings
    States easing virus restrictions despite experts' warnings
    Sponsored Content
    Get Free Newsletters

    Sign up for free enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today

    The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. We help you make informed business decisions and lead your organizations to success.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS
    • Instagram

    Stay Connected

    Join the conversation with Modern Healthcare through our social media pages

    MDHC_Logotype_white
    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2021. Crain Communications, Inc. All Rights Reserved.
    • News
      • This Week's News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Transformation
      • Patients
      • Operations
      • Care Delivery
      • Payment
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Award Programs
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Minorities in Healthcare
          • - Luminaries
          • - Top 25 Minority Leaders
          • - Minorities to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Nominate
      • Previous Award Programs
        • Excellence in Nursing Awards
        • Design Awards
        • Top 25 COOs in Healthcare
      • Other Award Programs
        • 100 Top Hospitals
        • ACHE Awards
    • Events
      • Conferences
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Healthcare Transformation Summit
        • Leadership Symposium
        • Virtual Briefings
          • - Hospital of the Future
          • - Mental Health
          • - Patient Safety & Quality
          • - Strategic Marketing
          • - Virtual Health
          • - Workplace of the Future
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Minority Leaders Gala
        • Top 25 Women Leaders Gala
      • Webinars
      • COVID-19 Event Tracker
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing